Exopharm Ltd (EX1)
20mins delayed
Movement
1 Year Return
Exopharm Ltd Chart
Share price | |
Last | |
Change | |
Volume | |
Turnover | |
Market Cap | $96.2 million |
Today's Movement | |
Prev. Close | |
Open | |
Day Range | - |
VWAP |
Historical Stats | |
52w Range | - |
4w Avg Volume | |
4w Avg Turnover | |
(delayed) |
EX1 Statistics
21 January
1,004 / 2,257
ASX Size Rank
1yr Return
vs Sector (1yr)
+143.92%
vs ASX 200 (1yr)
+159.89%
$96.2 million
Market Cap
Share Issue
139.41 million
All Ords (%)
N/A
Short Sold
0%
Current Fundamentals
21 January
N/A
PE Ratio
EPS ($)
-0.056
Earnings Yield
-8.14%
NTA ($)
0.04
0.00%
Dividend Yield
DPS ($)
-
Gross Div. Yield
-
Gross DPS ($)
-
Company Overview
Exopharm Limited (EX1) is a clinical-stage Australian exosome medicine company developing naive exosome products for regenerative medicine and engineered exosomes for new precision medicines. Exopharm owns a purification technology called Ligand-based Exosome Affinity Purification (LEAP).

Upcoming Calendar
Dividend History
Ex-Date | Amount | Franking | Type | Payable |
---|---|---|---|---|
No dividends paid in the last 5 years |
See Upcoming Dividends for all ASX companies.
Announcements
Date | Heading | Pages | File Size | Time |
---|---|---|---|---|
Announcements provided by

Broker Consensus
The buy, hold and sell recommendations from Australian stockbroking firms are combined to form a "broker consensus". See the Consensus Data posts for more information.
EX1 is not covered by a major broker,
or data from most recent compilation was omitted due
to not meeting QA guidelines.
Directors & Management
Director Transactions
EX1 directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
Date | Director | Type | Amount | Price | Value | Notes |
---|---|---|---|---|---|---|
13/09/19 | Jason Watson | Issued | 100,000 | $0.370 | $37,000 | Placement. |
19/08/19 | David Parker | Buy | +20,000 | $0.370 | $7,400 | Participation in share purchase plan. |
19/08/19 | Ian Dixon | Buy | +40,000 | $0.370 | $14,800 | Participation in share purchase plan. |
19/08/19 | Jason Watson | Buy | +40,000 | $0.370 | $14,800 | Participation in share purchase plan. |
Shareholder Distribution
Holding Size | 1 - 1,000 | 1,001 - 5,000 | 5,001 - 10,000 | 10,001 - 100,000 | 100,001 and over | Total Shareholders |
---|---|---|---|---|---|---|
No. of Shareholders | 31 | 184 | 173 | 561 | 156 | 1,105 |
Top 20 Shareholders
Name | Shares | Capital |
---|---|---|
Altnia Holdings Pty Ltd | 27,975,294 | 29.30% |
Mr Michael Francis Mcmahon & Mrs Susan Lesley Mcmahon | 2,276,849 | 2.38% |
Oldview Enterprises Pty Ltd | 1,432,585 | 1.50% |
Kohen Enterprises Pty Ltd | 1,350,000 | 1.41% |
Anthony John Locantro | 1,330,000 | 1.39% |
Phytose Corporation Pty Limited | 1,176,471 | 1.23% |
Carda Pty Ltd | 1,170,000 | 1.23% |
Mrs Anna Felicia Belton | 1,023,334 | 1.07% |
Zessham Pty Ltd | 950,000 | 1.00% |
Acns Capital Markets Pty Ltd | 800,000 | 0.84% |
Drp 2006 Super Pty Ltd | 760,000 | 0.80% |
Saintly Company Pty Ltd | 636,000 | 0.67% |
Kyriaco Barber Pty Ltd | 635,000 | 0.67% |
Mr John Gardner | 600,271 | 0.63% |
Gregor Lichtfuss | 588,235 | 0.62% |
Jeccs Pty Ltd | 545,000 | 0.57% |
Mr Wayne John Hogan & Mrs Angela Patrice Hogan | 500,000 | 0.52% |
Ringsford Pty Ltd | 500,000 | 0.52% |
Mr Andrew Stewart Coles & Ms Alexandra Constance Manook | 475,000 | 0.50% |
Aukera Capital Pty Ltd | 460,000 | 0.48% |
All other shareholders | 52.67 % |
The Top 20 Shareholders of EX1 hold 47.33% of shares on issue.
EX1 Share Price History
Date | Close | Change | % Change | Open | High | Low | Volume | Turnover |
---|---|---|---|---|---|---|---|---|
EX1 Historical Data
Download up to 20 years of share price history.
Year | Closing Price (30 June) | Last Trade |
---|---|---|
2020 | $0.25 | 30 June |
2019 | $0.41 | 28 June |
Offical data as published by ASX. See more Data Downloads.
Company Details
Principal Activity: Investment in biopharmaceutical drug development.
Incorporated: --
Level 1, 888 Doncaster Rd
Doncaster East VIC 3109

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.